ReviewCommunications medicine2026
Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.
Review in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains one of the most lethal malignancies because most patients are diagnosed with advanced disease, when curative treatment is rarely possible. Population-wide screening is not currently recommended because pancreatic cancer remains relatively uncommon. Early detection efforts therefore focus on surveillance of individuals at substantially elevated risk, including those with hereditary cancer syndromes, pathogenic germline variants, or a strong family history of pancreatic cancer. Surveillance is primarily performed using magnetic resonance imaging and endoscopic ultrasound to detect early-stage cancer or high-risk precursor lesions. In this Review, we summarise current evidence for pancreatic cancer surveillance in high-risk populations. We discuss approaches to risk identification, surveillance eligibility, imaging strategies, and reported clinical outcomes. We also examine important challenges, including interval cancers, risk stratification, psychological impact, cost-effectiveness, and implementation in clinical practice. Finally, we review emerging approaches, including biomarkers and risk prediction models, that may further improve early detection.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.